L. reuteri DSM 17938 — The Immune-Modulating Probiotic Strain
Limosilactobacillus reuteri DSM 17938 is a well-characterized probiotic strain originally isolated from human breast milk, widely used to treat functional gastrointestinal disorders. While its direct impact on human lifespan is unproven, its ability to reduce systemic inflammation, strengthen the intestinal barrier, and potentially activate metabolic sensors like AMPK makes it a compelling candidate for healthspan extension and age-related gut dysbiosis.
Mechanism of Action
Limosilactobacillus reuteri DSM 17938 colonizes the gastric and intestinal epithelium, where it exerts immunomodulatory and barrier-enhancing effects. It produces antimicrobial compounds such as reuterin, which inhibit pathogenic bacteria without harming beneficial commensals. The strain interacts with the intestinal mucosa to modulate the immune response, downregulating pro-inflammatory cytokines like TNF-α and IL-8 via NF-κB inhibition. Emerging evidence suggests it may also activate AMPK signaling via gut microbiota-derived propionate, potentially restoring mitochondrial biogenesis and offering metabolic benefits, though these longevity-specific pathways remain poorly characterized in humans.
Human Trial Evidence
No published human longevity trials. Animal/in-vitro evidence only. Extensive human trials exist for pediatric gastrointestinal disorders (infantile colic, acute diarrhea) and adult functional abdominal pain, demonstrating safety and efficacy in modulating gut motility and immune responses.
Dosing Protocol
100 million to 200 million CFU (colony-forming units) per day is the standard clinical dose, typically administered as 5 drops or 1 chewable tablet. Best taken with food to improve survival through gastric acid. Unestablished for direct longevity purposes in adults, but used continuously for gut health and immune modulation.
Safety & Contraindications
Generally recognized as safe (GRAS) with an excellent safety profile in both healthy infants and adults. Adverse effects are rare but may include mild, transient gastrointestinal discomfort such as bloating or gas upon initiation. Contraindicated in severely immunocompromised individuals, those with central venous catheters, or patients at high risk of bacteremia. No known significant drug interactions, though concurrent antibiotic use may reduce probiotic viability.